JenaValve has secured the FDA’s approval for its minimally invasive heart implant, making it the first to claim a U.S. green ...
The approval comes two months after Edwards Lifesciences scuttled plans to buy JenaValve for $945 million amid opposition ...
The FDA PMA for JenaValve's Trilogy device for TAVR-AR comes months after a court struck down Edwards Lifesciences attempt to ...
JenaValve's Trilogy System, FDA-approved for severe AR, offers secure anchoring without calcium. It is a breakthrough for ...
The FDA approved the Trilogy Transcatheter Heart Valve System for the treatment of symptomatic severe aortic regurgitation, ...
JenaValve announced today that it has received FDA premarket approval (PMA) for its Trilogy transcatheter heart valve system.
The FDA has approved the Trilogy Transcatheter Heart Valve System for treating patients with symptomatic severe aortic ...
PARIS -- The early commercial experience with transcatheter aortic valve replacement (TAVR or TAVI) for severe aortic regurgitation appeared promising, though device size issues and conduction ...
JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced that the U.S. Food and Drug Administration (FDA) has granted premarket ...
Please provide your email address to receive an email when new articles are posted on . A novel transcatheter heart valve system may be suitable for patients with noncalcified aortic valve disease who ...
Please provide your email address to receive an email when new articles are posted on . LAS VEGAS — A novel dicrotic notch index identified hemodynamically significant paravalvular aortic ...
Aortic insufficiency is a potentially severe condition that affects the heart’s ability to pump blood. There are many possible causes for this condition. Aortic insufficiency is a form of heart valve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results